Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT05609370

Public ClinicalTrials.gov record NCT05609370. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

Study identification

NCT ID
NCT05609370
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
BeiGene
Industry
Enrollment
113 participants

Conditions and interventions

Interventions

  • Alcestobart Drug
  • Tislelizumab Drug
  • Bevacizumab or Bevacizumab biosimilar Drug
  • Fluoropyrimidine (FP) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 28, 2023
Primary completion
May 22, 2025
Completion
Dec 30, 2026
Last update posted
Jun 29, 2026

2023 – 2026

United States locations

U.S. sites
30
U.S. states
17
U.S. cities
26
Facility City State ZIP Site status
Alaska Oncology and Hematology, Llc Anchorage Alaska 99508-2974
Banner Md Anderson Cancer Center Gilbert Arizona 85234-2165
Helios Clinical Research Cerritos California 90703
Valkyrie Clinical Trials Los Angeles California 90067-2011
Usc Norris Comprehensive Cancer Center (Nccc) Los Angeles California 90089-1019
UCLA Hematologyoncology Los Angeles California 90095-3075
Hoag Memorial Presbyterian Newport Beach California 92663-4162
Kaiser Permanente Northern California Vallejo California 94589-2441
Baptist Md Anderson Cancer Center Jacksonville Florida 32207-8432
Fort Wayne Medical Oncology and Hematology Fort Wayne Indiana 46804
Baptist Health Lexington Lexington Kentucky 40503-1466
University of Kentucky Markey Cancer Center Lexington Kentucky 40536-7001
Norton Cancer Institute Louisville Kentucky 40217-1395
Pontchartrain Cancer Center Covington Louisiana 70433-7512
Ochsner Clinic Foundation New Orleans Louisiana 70121-2429
Washington University School of Medicine St Louis Missouri 63110-1010
St Vincent Frontier Cancer Center Billings Montana 59102-6746
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169-3321
Cancer Care Specialists Reno Nevada 89511-2250
University of New Mexico Comprehensive Cancer Center Albuquerque New Mexico 87102-4517
Perlmutter Cancer Center At Winthrop Oncology Hematology Associatesnyu Winthrop Hospital Mineola New York 11501-3957
Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health New York New York 10016-2708
Columbia University Medical Center New York New York 10032
Duke Cancer Center Durham North Carolina 27710-2000
University of Tennessee Medical Center Knoxville Tennessee 37920-1511
Ut Southwestern Medical Center Dallas Texas 75390-7208
Ut Health San Antonio Mays Cancer Center San Antonio Texas 78229-4427
Virginia Cancer Specialists Fairfax Virginia 22031-2171
Cancer Care Northwest Spokane Valley Washington 99216-1020
Multicare Health System Institute For Research and Innovation Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05609370, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 29, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05609370 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →